Tobin W. Juvenal Sells 3,507 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the transaction, the insider now directly owns 54,178 shares in the company, valued at $1,926,569.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Castle Biosciences Trading Down 0.1 %

Shares of NASDAQ:CSTL opened at $33.29 on Friday. The company has a current ratio of 8.12, a quick ratio of 7.92 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1 year low of $16.20 and a 1 year high of $35.84. The firm has a fifty day moving average price of $30.92 and a 200 day moving average price of $25.87. The stock has a market capitalization of $919.14 million, a PE ratio of 166.46 and a beta of 0.99.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.50%. The company had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. During the same period in the prior year, the company earned ($0.26) earnings per share. Analysts expect that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

A number of hedge funds have recently bought and sold shares of CSTL. Acadian Asset Management LLC boosted its holdings in Castle Biosciences by 130.7% during the first quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock valued at $4,669,000 after acquiring an additional 119,443 shares during the period. Marshall Wace LLP lifted its stake in shares of Castle Biosciences by 116.5% in the second quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after buying an additional 114,104 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Castle Biosciences by 249.3% in the second quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock valued at $3,020,000 after buying an additional 99,001 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Castle Biosciences by 147.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock valued at $4,719,000 after buying an additional 98,571 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Castle Biosciences by 47.3% in the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock valued at $6,564,000 after buying an additional 96,800 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CSTL has been the topic of a number of research reports. Robert W. Baird upped their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday. Lake Street Capital upped their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday. KeyCorp upped their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stephens reiterated an “overweight” rating and issued a $37.00 price objective on shares of Castle Biosciences in a report on Tuesday, August 6th. Finally, Scotiabank upped their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $37.88.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.